Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A13355 | Pages: NA | Charts: NA | Tables: NA |
Ewing sarcoma is a type of a cancer which may be bone sarcoma or soft tissue sarcoma. Swelling & pain at the site of tumor, fever, and bone fractures are the common symptoms of Ewing sarcoma. Most common areas of Ewing sarcoma are legs, pelvis, and chest ribs. Histomorphologic findings, immunohistochemistry, and molecular pathology are most common methods of Ewing sarcoma diagnosis. Almost all patients are prescribed with multi drug chemotherapy such as vincristine, doxorubin, and others combined with surgery or radiation. Moreover, proton therapy also recommended to pediatric patient which delivers equally effective dose to the tumor and causes less damage to the surrounding tissue.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the Ewing sarcoma therapeutics pipeline market.
Top Impacting Factors
Market Trends
R&D Activities to Launch Novel Treatment Products
In 2018, Cellectar Biosciences Inc. received FDA approval for their novel drug CLR 131 for the treatment of Ewing sarcoma. This drug is an investigational radio iodinated phospholipid drug conjugate therapy for targeted tumor therapies.
In 2018, researcher at DNA-Farber, Boston Children Cancer and Blood Disorder Center discovered CDK12 inhibitor drug. This new drug is used for treatment of Ewing sarcoma and kill Ewing sarcoma cells.
Key Benefits of the Report
Questions Answered in the Ewing Sarcoma Therapeutics Pipeline Market Report
Key Market Segments
Key Market Players